Yvonne C Lee1, Bing Lu2, Hongshu Guan2, Jeffrey D Greenberg3, Joel Kremer4, Daniel H Solomon2. 1. Northwestern University Feinberg School of Medicine, Chicago, Illinois, and Brigham and Women's Hospital, Boston, Massachusetts. 2. Brigham and Women's Hospital, Boston, Massachusetts. 3. Corrona, LLC, Waltham, Massachusetts, and New York University, New York, New York. 4. Corrona, LLC, Waltham, Massachusetts, and Albany Medical College, Albany, New York.
Abstract
OBJECTIVE: To identify the extent to which opioid prescribing rates for patients with rheumatoid arthritis (RA) vary in the US and to determine the implications of baseline opioid prescribing rates on the probability of future long-term opioid use. METHODS: We identified patients with RA from physicians who contributed ≥10 patients within the first 12 months of participation in the Corrona RA Registry. The baseline opioid prescribing rate was calculated by dividing the number of patients with RA reporting opioid use during the first 12 months by the number of patients with RA providing data that year. To estimate odds ratios (ORs) for long-term opioid use, we used generalized linear mixed models. RESULTS: During the follow-up period, long-term opioid use was reported by 7.0% (163 of 2,322) of patients of physicians with a very low rate of opioid prescribing (referent) compared to 6.8% (153 of 2,254) of patients of physicians with a low prescribing rate, 12.5% (294 of 2,352) of patients of physicians with a moderate prescribing rate, and 12.7% (307 of 2,409) of patients of physicians with a high prescribing rate. The OR for long-term opioid use after the baseline period was 1.16 (95% confidence interval [95% CI] 0.79-1.70) for patients of low-intensity prescribing physicians, 1.89 (95% CI 1.27-2.82) for patients of moderate-intensity prescribing physicians, and 2.01 (95% CI 1.43-2.83) for patients of high-intensity prescribing physicians, compared to very low-intensity prescribing physicians. CONCLUSION: Rates of opioid prescriptions vary widely. Our findings indicate that baseline opioid prescribing rates are a strong predictor of whether a patient will become a long-term opioid user in the future, after controlling for patient characteristics.
OBJECTIVE: To identify the extent to which opioid prescribing rates for patients with rheumatoid arthritis (RA) vary in the US and to determine the implications of baseline opioid prescribing rates on the probability of future long-term opioid use. METHODS: We identified patients with RA from physicians who contributed ≥10 patients within the first 12 months of participation in the Corrona RA Registry. The baseline opioid prescribing rate was calculated by dividing the number of patients with RA reporting opioid use during the first 12 months by the number of patients with RA providing data that year. To estimate odds ratios (ORs) for long-term opioid use, we used generalized linear mixed models. RESULTS: During the follow-up period, long-term opioid use was reported by 7.0% (163 of 2,322) of patients of physicians with a very low rate of opioid prescribing (referent) compared to 6.8% (153 of 2,254) of patients of physicians with a low prescribing rate, 12.5% (294 of 2,352) of patients of physicians with a moderate prescribing rate, and 12.7% (307 of 2,409) of patients of physicians with a high prescribing rate. The OR for long-term opioid use after the baseline period was 1.16 (95% confidence interval [95% CI] 0.79-1.70) for patients of low-intensity prescribing physicians, 1.89 (95% CI 1.27-2.82) for patients of moderate-intensity prescribing physicians, and 2.01 (95% CI 1.43-2.83) for patients of high-intensity prescribing physicians, compared to very low-intensity prescribing physicians. CONCLUSION: Rates of opioid prescriptions vary widely. Our findings indicate that baseline opioid prescribing rates are a strong predictor of whether a patient will become a long-term opioid user in the future, after controlling for patient characteristics.
Authors: Barbara Ellen Jones; Brian Sauer; Makoto M Jones; Jose Campo; Kavitha Damal; Tao He; Jian Ying; Tom Greene; Matthew Bidwell Goetz; Melinda M Neuhauser; Lauri A Hicks; Matthew H Samore Journal: Ann Intern Med Date: 2015-07-21 Impact factor: 25.391
Authors: Nancy N Maserejian; Michael A Fischer; Felicia L Trachtenberg; Jing Yu; Lisa D Marceau; John B McKinlay; Jeffrey N Katz Journal: Arthritis Care Res (Hoboken) Date: 2014-01 Impact factor: 4.794
Authors: Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen Journal: Arthritis Res Ther Date: 2005-04-07 Impact factor: 5.156
Authors: Reem Altawil; Saedis Saevarsdottir; Sara Wedrén; Lars Alfredsson; Lars Klareskog; Jon Lampa Journal: Arthritis Care Res (Hoboken) Date: 2016-08 Impact factor: 4.794
Authors: Simona D'Agnelli; Lars Arendt-Nielsen; Maria C Gerra; Katia Zatorri; Lorenzo Boggiani; Marco Baciarello; Elena Bignami Journal: Mol Pain Date: 2018-11-29 Impact factor: 3.395